Status:
COMPLETED
Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients
Lead Sponsor:
Aronex Pharmaceuticals
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to see if it is safe and effective to give zintevir (AR177) to asymptomatic (no symptoms) HIV-infected patients. Zintevir belongs to a new class of anti-HIV drugs, the in...
Detailed Description
Zintevir belongs to a new class of anti-HIV drugs, the integrase inhibitors. The HIV-1 virus uses the protein integrase to incorporate its genetic material into the infected host cell. Integrase inhib...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- You may be eligible for this study if you:
- Are HIV-positive, but do not have any symptoms of HIV infection.
- Have a CD4 count greater than 200 cells/mm3.
- Have a viral load (level of HIV in the body) greater than 4,000 copies/ml.
- Are at least 18 years old.
- Exclusion Criteria
- You will not be eligible for this study if you:
- Tend to have abnormal bleeding or other blood problems.
- Have an active AIDS-defining illness.
- Have a history of serious disease or illness.
- Abuse alcohol or drugs.
- Have received certain medications.
Exclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00002403
Last Update
June 24 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cornell AIDS Clinical Trials Unit
New York, New York, United States, 10021